PROSTATE CANCER FOLLOWING TESTOSTERONE REPLACEMENT IN KLINEFELTER SYNDROME

Klinefelter syndrome is a common cause of hypogonadism. Testosterone replacement therapy has beneficial effects on bone, muscle and psychosexual function. However, it may remove the relative protection from adenocarcinoma of prostate, which is otherwise rare in uncomplicated Klinefelter syndrome. We report the case of a 55‐year‐old man with Klinefelter syndrome who developed prostate cancer after only 7 years of androgen supplementation. Androgen deprivation therapy was complicated by the presence of testosterone implants. The patient was treated with androgen blockade followed by radiation therapy. We recommend that serum prostate specific antigen (PSA) and digital rectal examinations be carried out during, as well as before androgen replacement.

[1]  J. Richie,et al.  Prostate cancer after exogenous testosterone treatment for impotence. , 1997, The Journal of urology.

[2]  R. Oliver,et al.  Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. , 2000, Drugs & aging.

[3]  E. Cannell,et al.  [Klinefelter syndrome]. , 2005, Revue medicale suisse.

[4]  M. J. Curran,et al.  Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. , 1999, Urology.

[5]  A. Morales Androgen replacement therapy and prostate safety. , 2002, European urology.

[6]  S. Ishikawa,et al.  Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. , 1989, The Journal of urology.

[7]  A. Guay,et al.  Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  M. Marberger,et al.  Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. , 2003, The Journal of urology.

[9]  L. Meisner,et al.  Adenocarcinoma of the prostate in a 41-year-old man with XXY karyotype and chronic lymphocytic leukemia: report of a case. , 1991, The Journal of urology.

[10]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[11]  J. Hansen,et al.  Cancer incidence in men with Klinefelter syndrome. , 1995, British Journal of Cancer.

[12]  L. Arduino Carcinoma of the prostate in sex chromatin positive (XXX/XY) Klinefelter's syndrome. , 1967, The Journal of urology.

[13]  R. Prehn On the prevention and therapy of prostate cancer by androgen administration. , 1999, Cancer research.